Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.07.2021 | Case report

Dexamethasone/hydroxycarbamide/lenalidomide

Various toxicities: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Loscocco GG, et al. Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. American Journal of Hematology 96: 749-754, No. 6, 1 Jun 2021. Available from: URL: http://doi.org/10.1002/ajh.26153 Loscocco GG, et al. Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. American Journal of Hematology 96: 749-754, No. 6, 1 Jun 2021. Available from: URL: http://​doi.​org/​10.​1002/​ajh.​26153
Metadaten
Titel
Dexamethasone/hydroxycarbamide/lenalidomide
Various toxicities: case report
Publikationsdatum
01.07.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-99844-4

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Antineoplastics

Case report

Interferon-β-1a

Case report

Abemaciclib